Showing results (241-250 of 653) with videos related to

Sort By:
Pageof 66
Cancer Discovery|September 23, 2021
Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion StudyFunda Meric-Bernstam, Rastislav Bahleda, Cinta Hierro, et al.
Oncotarget|May 17, 2018
Signature program: a platform of basket trialsEric D Slosberg, Barinder P Kang, Julio Peguero, et al.
Cancer|August 13, 2011
Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancersKanwal P S Raghav, Leonel F Hernandez-Aya, Xiudong Lei, et al.
Cancer|June 22, 2010
Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancerLaura S Dominici, Viviana M Negron Gonzalez, Aman U Buzdar, et al.
Molecular Cancer Therapeutics|July 7, 2023
Safety and Tolerability of a Novel Anti-HER2 Antibody-Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation StudyFunda Meric-Bernstam, Emiliano Calvo, Keun Seok Lee, et al.
Oncotarget|July 1, 2014
Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancerShuying Liu, Xiaolong Meng, Huiqin Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2026
Zanidatamab, a Dual HER2-Targeted Bispecific Antibody, in Patients With Unresectable Locally Advanced or Metastatic HER2-Positive Salivary Gland Cancer: A Combined Analysis of Early-Phase StudiesKeun-Wook Lee, Elena Elimova, Do-Youn Oh, et al.
The Oncologist|September 4, 2007
Trends for inflammatory breast cancer: is survival improving?Ana M Gonzalez-Angulo, Bryan T Hennessy, Kristine Broglio, et al.
Molecular Cancer Therapeutics|September 30, 2010
Rapamycin regulates stearoyl CoA desaturase 1 expression in breast cancerDavid Luyimbazi, Argun Akcakanat, Priscilla F McAuliffe, et al.
The Lancet. Oncology|November 19, 2013
Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trialAman U Buzdar, Vera J Suman, Funda Meric-Bernstam, et al.
Pageof 66